Oncolytics Biotech Inc. (ONCY) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Oncolytics Biotech Inc. (NASDAQ: ONCY) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $0.43 (-3.15% 1D, market cap $56.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ONCY ranks #418 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ONCY carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HRTX (Heron Therapeutics Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $55.9M) and TLPH (Talphera Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $55.5M). Among the 5-stock peer group, ONCY leads on earnings multiple (N/A) while ONCY leads on capital efficiency (-35.0% ROIC).
Per ONCY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001129928), Oncolytics Biotech Inc. generated $0 in revenue, -$28.8M in net income, and -$20.1M in free cash flow against $7.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While ONCY currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.67) and Max Pain ($0.45) forces dealer call-delta covering toward $1.37.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Oncolytics Biotech Inc. (ONCY) dropped -3.15% to $0.43, trading at 2% of its 52-week range ($0.41 – $1.3). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
GOBLET Cohort 4 demonstrates approximately 15-month median duration of response that exceeds historical results for approved second-line checkpoint inhibitor monotherapy 100% of responding patients survived for longer th
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced updated data from Cohort 4 of its Phase 1/2 GOBLET
Study launched earlier this year is expected to confirm previous efficacy signal in 2L KRAS-mutant MSS colorectal cancer study that saw 17 months PFS vs. 6 months for the historical standard of careSAN DIEGO, Oct. 20, 20
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the Company is presenting a trial-in-progress
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ONCY today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ONCY. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Oncolytics Biotech Inc. (ONCY) ranks #418 by composite RQD confidence (45/100, grade D) and #732 by equity capitalization ($56.1M). Within this direct 5-issuer industry benchmark cohort, ONCY leads on earnings valuation at N/A trailing P/E, while ONCY leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ONCY currently leads its immediate peer cohort in composite quantitative strength at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ONCY
ACTIVE
Oncolytics Biotech Inc. | D | 45/100 | — | — | -35.0% | -3.15% | $56.1M | Benchmark Subject |
| HRTX Heron Therapeutics Inc. | D- | 37/100 | — | 73.3% | -35.0% | -4.69% | $55.9M | /hrtx-vs-oncy → |
| TLPH Talphera Inc. | D- | 42/100 | — | — | -35.0% | -1.83% | $55.5M | /tlph-vs-oncy → |
| CLNN Clene Inc. | E | 34/100 | — | 78.5% | -35.0% | -3.23% | $55.4M | /clnn-vs-oncy → |
| NMAD Nomad Power Solutions Inc. | E | 33/100 | — | — | -35.0% | -12.16% | $57.0M | /nmad-vs-oncy → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Oncolytics Biotech Inc. (ONCY) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$28.8M, operating cash flow of -$20.1M, and free cash flow of -$20.1M (-0.3% YoY). On the balance sheet, ONCY closed FY2025 with $7.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$28.8M | -$20.1M | -$20.1M | $7.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$22.8M | -$19.9M | -$20.1M | $13.4M | — |
As of 2026-11-02, Oncolytics Biotech Inc. (NASDAQ: ONCY) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $0.43 (-3.15% 1D, market cap $56.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ONCY ranks #418 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ONCY carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HRTX (Heron Therapeutics Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $55.9M) and TLPH (Talphera Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $55.5M). Among the 5-stock peer group, ONCY leads on earnings multiple (N/A) while ONCY leads on capital efficiency (-35.0% ROIC).
Per ONCY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001129928), Oncolytics Biotech Inc. generated $0 in revenue, -$28.8M in net income, and -$20.1M in free cash flow against $7.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ONCY last traded at $0.43 (-3.15% on volume of 607,287 shares), positioning the stock -35.82% below its 50-day simple moving average ($0.67) and -50.00% below its 200-day simple moving average ($0.86). Across its 52-week range of $0.41 to $1.30, ONCY sits at the 2.2% percentile with a 14-day RSI of 24.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.48).
Why ONCY Stock dropped -3.15% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).